To evaluate the origin of cells after allogeneic haematopoietic stem cell transplantation we optimised and evaluated two commercially available systems (AmpFlSTR Profiler Plus and GenePrint Powerplex-16) which are based on multiplex fluorescent short tandem repeat (STR) analysis. A standard procedure for interpretation of electropherographs was found essential to obtain reproducible results. On the basis of the relative length of donor and recipient alleles, TYPE-I (no shared alleles are used to calculate chimerism), TYPE-II (one shared and one unshared allele is used to calculate chimerism) or TYPE-III (not informative) allelic distribution types were distinguished. Also, stutter peaks were recognised as an important criterion to exclude a marker for analysis. Intralaboratory and multicentre evaluation of the AmpFlSTR Profiler Plus system showed that mixed blood samples could be determined with an absolute deviation of less than 2%. A sensitivity threshold was set at 5% for TYPE-I and 10% for TYPE-II markers since relative imprecision increases at low chimerism values. No significant difference of calculated chimerism values was observed between STR markers shared between both systems. By monitoring 26 allogeneic peripheral blood stem cell transplants, the applicability of the proposed method was demonstrated. Bone Marrow Transplantation (2001) 28, 511-518.
fingerprint of an individual, which allows donor cells to be distinguished from host cells. Variable number of tandem repeats (VNTRs) were shown to be most useful because of their high probability of being informative as they consist of multiple alleles allowing simplicity of analysis on a routine basis. Two major types of VNTRs exist: minisatellites, which contain repeat units of 6 to Ͼ50 nucleotides and microsatellites or short tandem repeats (STRs), which comprise simple nucleotides to pentanucleotide repeats. 1 More than 10 4 STRs are estimated to be present within the human genome, and for each of them PCR amplification can potentially be used to perform chimerism analysis if its product length is polymorphic among the human population.
Chimerism testing after allogeneic transplantation can be used to monitor donor engraftment or to diagnose relapse. Clinical interpretation of chimerism testing varies since several patients have been shown to have stable mixed chimerism. Therefore, serial analysis of chimerism is essential in most patients as it enables observation of evolving cellular processes. In addition, non-myeloablative stem cell transplantation is dependent on rapid analysis of the degree of mixed chimerism of T lymphocytes to schedule therapeutic interventions. 2 Also, in patients who are candidates for a second allogeneic transplant or donor lymphocyte infusion for recurrent malignancy, persistence of donor cells indicates that the recipient is still tolerant of the graft.
Because chimerism analysis is an important tool in haematopoietic stem cell transplantation, a standardised method for chimerism testing is needed. This study is aimed at optimising, and intralaboratory, interlaboratory and clinical evaluation of a method for chimerism analysis using commercially available human identification systems. Two systems were compared, both amplifying polymorphic STR markers distributed throughout the human genome, followed by detection of the fluorescently labelled PCR products by capillary electrophoresis.
Materials and methods

Optimisation of the chimerism assay
DNA was prepared from whole blood or whole bone marrow using the QIAamp Blood Kit (Qiagen, Hilden, Germany) according to the instructions provided by the manufacturer. This column exchange DNA preparation method was used to obtain high quality DNA devoid of PCR inhibitors. DNA quantification was performed by spectrophotometry. Polymorphic STR markers were amplified using the AmpFlSTR Profiler Plus PCR amplification kit (Applied Biosystems, Foster City, CA, USA) or the GenePrint Powerplex-16 system (Promega, Madison, WI, USA). The following nine STR markers were amplified in both systems: D3S1358, FGA, D5S818, D7S820, D8S1179, vWA, D13S317, D18S51 and D21S11. The GenePrint Powerplex-16 system additionally contains the STR markers CSF1PO, THO1, TPOX, Penta E, D16S539 and Penta D. The amylogenin marker is included in both systems to enable gender identification. It amplifies specific products at the X and Y chromosome which are respectively 107 bp and 113 bp long.
For each locus one fluorescently labelled primer was used (either 5-FAM, JOE or NED for the AmpFlSTR Profiler Plus system or Fluorescein, JOE, TMR or CXR for the GenePrint Powerplex-16 system). For each system all markers were amplified in a multiplex PCR reaction (thermal cycler PTC-200, MJ Research, Watertown, MA, USA). Primers, buffer reagents and TAQ polymerase were used according to the manufacturer's instructions. To prevent stochastic bias by using only 1-2.5 ng of input DNA (as recommended by the manufacturers) and to enable analysis when only small amounts of DNA were available, we used 25 ng of template DNA which corresponds to approximately 3000 diploid cells. Aiming at the equal amplification of all markers the number of PCR cycles was varied. The following PCR cycling conditions were compared for the AmpFlSTR system and are basically the same as instructed by the manufacturer: after an initial denaturation of 11 min at 95°C, either 22, 24, 26 or 28 PCR cycles were performed at 94°C for 1 min, 59°C for 1 min and 72°C for 1 min. After the reaction, an additional incubation step at 60°C for 1 h was added to enable full A-addition to the PCR products. The cycling programs used to test the Geneprint Powerplex-16 system were also in line with the manufacturer's instructions: an initial denaturation of 11 min at 95°C was followed by (part 1) 10 PCR cycles of 94°C for 30 s, 60°C for 30 s, ramping at 0.2°C/s to 70°C and 70°C for 45 s followed by (part 2) 16, 18, 20 or 22 cycles of 90°C for 30 s, 60°C for 30 s, ramping at 0.2°C/s to 70°C and 70°C for 45 s. Finally, an incubation step at 60°C for 30 min was added to enable full A-addition to the PCR products.
Fragments were analysed on the ABI PRISM 310 Genetic Analyzer (Applied Biosystems). Thus, 2 or 1 l of the PCR reaction mix, for the AmpFlSTR Profiler Plus or Geneprint Powerplex-16 system respectively, was added to 24 l of deionized formamide (Sigma, St Louis, MO, USA) and 1 l of ROX-500 size standard (Applied Biosystems) or Internal Lane Standard 600 (Promega). Electrophoresis was performed using the Performance Optimized Polymer 4 (Applied Biosystems) with a 47 cm/50 m capillary. Samples were injected over 3 s, and electrophoresis was performed according to the manufacturer's instructions. The Genescan software (Applied Biosystems) was used for size calling and quantification of peak areas.
For the multicentre analysis DNA preparation was done by each laboratory. Four laboratories used the QIAamp Blood Preparation kit (Qiagen), one laboratory used a classical phenol/chloroform extraction method. 3 Chimerism analysis was performed by the five laboratories using the AmpFlSTR Profiler Plus system as described above.
Preparation of mock mixed chimeric samples
Blood from healthy donors was collected using acid citrate dextrose as the anticoagulating agent. The concentration of white blood cells (WBC) was determined using a Coulter STKS automatic cell counter (Coulter, South San Francisco, CA, USA). For standard curve construction blood samples from two unrelated normal donors were mixed with respect to the concentration of their white blood cells as a 1:2 serial dilution (50%, 25%, 12.5%, 6.25%, 3.12% and 1.56% mixture).
Multicentre variation was tested by analysing blood samples from a healthy brother and sister which were prepared as 50%, 40% and 10% mixtures. These mixtures were sent as whole blood to the five participating laboratories.
Patients
Twenty-six patients treated for a variety of haematological malignancies at the AZ Sint-Jan AV, Bruges, Belgium were transplanted with allogeneic peripheral blood stem cells using myeloablative conditioning protocols. Blood samples were collected from recipient and donor prior to transplantation. Pretransplant diseases were chronic myelogeneous leukaemia (CML, n = 3), acute myelogeneous leukaemia (AML, n = 4), myelodysplastic syndrome (MDS-RAEBt, n = 7), acute lymphoblastic leukaemia (ALL, n = 2), multiple myeloma (MM, n = 2), non-Hodgkin's lymphoma (NHL, n = 7), polycythemia vera (n = 1) and aplastic anaemia (n = 1). For 24 patients the donor was an HLAidentical sibling; one patient was transplanted with a HLA mismatched family donor and one with an unrelated donor. Blood or bone marrow samples were taken at various time points after transplantation and tested using the AmpFlSTR Profiler Plus System.
Results
Optimisation of the amplification step
We optimised the use of two commercial systems, the AmpFlSTR Profiler Plus system (Applied Biosystems) and the GenePrint Powerplex-16 system (Promega) for chimerism testing. Both kits were developed for human identification, and therefore only a minimal amount of DNA (1 to 2.5 ng) is used as a template for amplification. We adapted the procedure to use 25 ng as input DNA, which corresponds to approximately 3000 diploid cells. This was necessary to prevent stochastic bias when examining low values of either donor or recipient chimerism. Subsequently, we found that a reduction in the number of PCR cycles with respect to the manufacturer's instructions was needed to result in equal peak heights for, respectively, all homozygous and heterozygous markers, irrespective of their fragment length. The use of 24 cycles for amplifi-cation of the AmpFlSTR Profiler plus system, and 28 cycles (10 for part 1 plus 18 for part 2 of the cycling program) for the GenePrint Powerplex-16 system was found to be optimal (data not shown).
Standard procedure for interpretation of electropherographs
After electrophoresis chimerism values were calculated from the observed peak areas of the informative markers. Standardisation of the calculation procedure was needed to obtain reproducible chimerism values. Therefore, first the length of recipient and donor alleles of all markers was determined by performing the analysis (as described in Materials and methods) both on donor and recipient DNA isolated before transplantation. All markers were scored for their allele lengths. The relative positions of both donor and recipient alleles of a given marker determined its suitability for chimerism calculation. All possibilities were grouped in three allelic distribution types ( Figure 1 ).
In TYPE-I only alleles not shared between donor and recipient were used to calculate chimerism values. Bone Marrow Transplantation donor chimerism was calculated by dividing the peak areas of donor allele(s) (Ad) by the sum of the peak areas of donor (Ad) and recipient (Ar) alleles. In TYPE-II one shared and one unshared allele had to be used for calculation of chimerism values. The two possible combinations and the proposed calculation formula are shown in Figure 1 .
In TYPE-III all alleles were shared between donor and recipient and therefore the marker was not informative for chimerism testing.
Precision and accuracy of calculating chimerism on the basis of TYPE-I allelic distribution types
Intralaboratory: To simulate a range of mixed chimerism samples, we prepared mock transplant samples by mixing blood from two healthy unrelated donors (range 1.56% to 50%). Chimerism analysis of the donor's DNA showed that nine and 13 markers were of TYPE-I for the AmpFlSTR Profiler Plus and the GenePrint Powerplex-16 system, respectively. Furthermore, either four or seven markers needed to be excluded because of interference of stutter peaks (for criteria for exclusion on the basis of stutter peaks
Bone Marrow Transplantation see below). Figure 2 shows mean and standard deviation of the chimerism analysis using the AmpFlSTR Profiler Plus system of each mock sample for all five selected markers. Accurate measurement of each mixture is illustrated, as the observed percent chimerism for each sample differs less than 1.7% from the prepared mixing ratio. Moreover, a standard deviation of less than 2.1% was found for the markers used to determine percent chimerism in a sample. The same mock samples were evaluated using the GenePrint Powerplex-16 system. A comparison of both systems is depicted in Figure 3 , and illustrates no significant differences in chimerism determination for all samples. Variation of chimerism values obtained for each individual marker range from 0% to 2.8% (mean 1.08%), which is comparable with the variation observed when mock samples were repeatedly analysed using the AmpFlSTR Profiler plus system (data not shown).
To determine sensitivity of chimerism analyses we plotted the coefficient of variation vs the observed percent chimerism for each mock sample (Figure 4) . Exponential increase in CV, and consequently less precise determination of chimerism is observed at low percent chimerism. Therefore, the detection limit for our assay was deliberately set to 5% for the least abundant genotype of the mixture, corresponding to a CV of approximately 20%.
Interlaboratory: Five laboratories participated in a multicentre experiment. Three mixed blood samples (50%, 40% and 10% mixtures) were distributed and the percent of chimerism was determined using the AmpFlSTR Profiler Plus kit and the ABI PRISM 310 Genetic Analyzer. Seven markers were of TYPE-I, of which two markers were excluded because of interference of stutter peaks (for exclusion criteria see below). Reported chimerism values and standard deviation of the measurement of all markers for each sample are depicted in Figure 5 . Average absolute deviation (absolute deviation = reported chimerism minus mixing ratio of sample) was found to be less than 1% and the range of chimerism values reported by the five laboratories was less than 3%.
Precision and accuracy of calculating chimerism on the basis of TYPE-II allelic distribution types
Donor and patient DNA of UPN 12 obtained before stem cell transplantation was used to prepare DNA mixtures as a 1:2 serial dilution (50%, 25%, 12.5%, 6.25%, 3.12% and 1.56% mixtures). These samples were selected because five informative TYPE-II markers without interference of stutter peaks were present (Table 1) . Chimerism values were obtained using the AmpFlSTR Profiler Plus system and are summarised in Figure 6 . As expected, determination of chimerism values was observed to be less precise compared to TYPE-I markers. Although mean values of all five TYPE-II markers for each sample show that the accuracy (less than 2.7%) is similar to TYPE-I markers, precision is lower as illustrated by the increased standard deviation values (up to 4.2%). Consequently, the detection limit for TYPE-II markers was also set to 10%, corresponding to a CV of approximately 40% (Figure 4) . Moreover, as for all TYPE-II markers three alleles are co-migrating as the shared allele, a signal which is too intense for this peak frequently impedes quantitative detection by the ABI PRISM 310 Genetic Analyzer.
Interference of stutter peaks
Some markers had to be excluded from the analysis because of interference of stutter peaks. Stutter peaks are produced when amplifying DNA fragments contain STR sequences, and are due to slipping amplification by the TAQ polymerase. They consist of a PCR product peak, which is missing one core repeated unit compared to the original allele. The amount of stutter product is dependent on both marker and allele size. It is proportional to the amount of original allele and was determined to be a maximum of 13% (range Ͻ0.5-13%) (personal communication, Promega Corp). 5 To avoid possible significant interference of a stutter peak at low peak values, we excluded each marker from analysis if one of its alleles used to calculate chimerism was comigrating with a stutter peak, and if its peak area was less than the peak area of the allele-specific fragment producing the stutter peak (see also Figure 7 ). Using this criterion, the possible contribution of a stutter product to a peak area was a maximum of 13%. Moreover, since the stutter peak area is proportional to the peak area of the allele-specific fragment producing the stutter peak, the interference of stutter product is negligible when the amount of allele-specific fragment producing the stutter peak is small; for example, when Ar is only 10% of the Ad, the stutter band constitutes less than 1.5% of Ad (see Figure 7) . 
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Figure 7
Illustration of the criteria for exclusion of a marker on the basis of stutter peak interference. Example shows a tetranucleotide marker where a donor allele (allele length n-4) is co-migrating with a stutter peak of a recipient allele (allele length n). The arrow points at the stutter peak. Ad and Ar represent peak areas of donor and recipient alleles, respectively.
Analysis of chimerism in patients undergoing allogeneic stem cell transplantation
Twenty-six patients were analysed at different time points after transplantation for their chimerism status using the AmpFlSTR Profiler plus system. All except two (UPN 18 and 24) were transplanted from a sibling donor. Samples taken before transplantation were used to score allelic lengths for each marker for both donor and recipient and to determine their suitability for chimerism calculation. Since a sibling donor, who is sharing genetic parental background with the recipient, was used for transplantation in 24 cases, one might expect a significantly reduced number of informative markers. Table 1 summarises the number of markers of a particular allelic distribution type and number of markers devoid of stutter interference with application of proposed exclusion criteria. For all patients transplanted at all time points (n = 339) at least one marker of TYPE-I or TYPE-II could be used for analysis. For high or low donor chimerism values our outlined criteria for exclusion of markers on the basis of stutter peaks still allowed inclusion of several markers with possible stutter interference in the analysis, as indicated in Table 1 . UPN 6, 9 and 17 were found to have no informative marker of TYPE-I available for chimerism calculation at all or particular chimerism values. For these patients we additionally used the 16 markers of the GenePrint Powerplex-16 system resulting in at least one TYPE-I marker suitable for analysis for UPN 6 and 9. For UPN 17 no additional TYPE-I marker was found for Ͼ50% donor chimerism values.
Our preliminary results showed that 12 patients, all in complete remission, were in full chimerism (Ͼ95% donor chimerism) at all time points. Mixed chimerism (donor chimerism between 5% and 95%) was observed in three patients in stable remission. Mixed donor chimerism values ranged from 79.2 to 90.2% (four time points for UPN 2), 12.8 to 23.0% (six time points for UPN 6) and 26.6 to 42.2% (five time points for UPN 21). Six patients (one CML, three MDS-RAEBt, one AML and one MM) could be followed during disease relapse. In the AML and the three MDS-RAEBt patients a decrease in donor chimerism was found to parallel an increase in number of blasts. On the other hand, as expected, quantitative BCR-ABL RT-PCR analysis of the CML patient was able to predict relapse prior to decrease in donor chimerism due to higher sensitivity of this technique (data not shown).
Discussion
We adapted the AmpFlSTR Profiler Plus and GenePrint Powerplex-16 system, commercialised as human identification systems, to be used for chimerism analysis. Basically, we increased the amount of template DNA (to 25 ng) and decreased the number of PCR cycles (to 24 or 28, respectively) to allow equal amplification of all loci. Other reports on chimerism analysis based on commercially available human identification systems are using only 1-2 ng of template DNA. [6] [7] [8] However, when using 25 ng, which corresponds to DNA isolated from 3000 diploid cells, less stochastic interference in the results should be guaranteed, especially when analysing minimal donor or recipient mixed chimeras. Also, when low cell numbers are present 25 ng DNA is still likely to be available for analysis (eg during aplasia).
Using a series of mock chimeric samples, eminent linearity (R 2 Ͼ 0.99), accuracy (deviation bias Ͻ1.7%) and precision (s.d. Ͻ 2.1%) were observed for TYPE-I markers using the AmpFlSTR Profiler Plus system. Analyses of the same mock samples using the GenePrint Powerplex-16 system indicated no significant differences between either method. The reproducibility of our method was confirmed by a multicentre analysis of TYPE-I markers showing an average absolute deviation of results of less than 1% mixing ratio, a percentage so low that it may even be within the mixing error of the sample preparation. These results are comparable with a recently reported multicentre analysis of 20 DNA samples in three different laboratories using the AmpFlSTR Profiler Plus system. 8 Like others, using mock chimeric samples, we were able to detect minor chimeric cell populations (Ͻ1%). However, sensitivity varied between loci. 7, 9, 10 Moreover, the relative imprecision (coefficient of variation) was found to increase at low chimerism values. Therefore, a sensitivity threshold was set at 5% for TYPE-I and 10% for TYPE-II allelic distribution types. A 5% detection limit was also proposed in several other reports. 6, 7 For the interpretation of mixed pattern donor-and recipient-specific peaks a standardised approach was validated. This was found to be essential to obtain reproducible and accurate percent chimerism values. First, alleles of donor and recipient needed to be analysed and categorised in TYPE-I (only unshared alleles are used to calculate chimerism), TYPE-II (one shared and one unshared allele are used to calculate chimerism) or TYPE-III (not informative) allelic distribution types. Due to less precise chimerism determination for TYPE-II allelic distributions, these markers were preferentially excluded from analysis. This observed imprecision is probably due to the doubling of the non-shared alleles for calculation of donor chimerism values (see formulas in Figure 1) .
We also found cross-interference by stutter peaks to be an important reason for exclusion of a marker. To avoid possible significant interference at low peak values, we only analysed markers with stutter interference if the peak area of the allele, co-migrating with a stutter fragment, was larger than the allele producing the stutter fragment. In contrast to many other reports, 7, 8, 11 we excluded a substantial number of informative markers from analysis on the basis of this criterion (see Table 1 ). However, the extent of stutter peak interference is highly variable among different markers. The proportion of stutter product relative to the main allele producing the stutter fragment ranges from Ͻ0.5% to 13%, dependent both upon locus and allele. Stutter interference is smallest (Ͻ5%) for pentameric repeats, of which two are included in the GenePrint Powerplex-16 system. In the future, if specific assays for chimerism assays are developed on the basis of these pentameric repeats, interference of stutter peaks could become negligible. Meanwhile, as each allele within a locus produces a reproducible stutter peak (s.d. Ͻ0.8%) 5 an alternative, although labourintensive approach could correct stutter interference based on the analyses performed on donor and recipient before transplantation.
All markers except two for the GenePrint Powerplex-16 system are distributed on different chromosomes. Due to the high number of markers, the described method for chimerism testing is very likely to result in several informative markers when allogeneic transplantation is performed from an unrelated donor. However, the number of informative markers might be significantly reduced for sibling donor/recipient pairs since they share the same genetic background as their parents. In our preliminary study on 26 transplant patients using the AmpFlSTR Profiler Plus system at least one TYPE-I or TYPE-II marker could be used for analysis at all time points. Caution should, howBone Marrow Transplantation ever, be taken if only one informative marker is available for consecutive donor chimerism evaluation, since loss of specific chromosomal regions during clonogenic evolution was found to occur in several haematological malignancies. 12 Therefore, the use of even more markers is warranted. Indeed, the use of the GenePrint Powerplex-16 system, which contains six other markers in addition to the ones included in the AmpFlSTR Profiler Plus system, resulted in additional informative markers for two of three patients analysed.
Determination of chimeric status using STR markers was recently described as useful for monitoring minimal residual disease in patients after allogeneic stem cell transplantation. 13, 14 However, our observation of reduced accuracy at low percent chimerism values impedes this application. Detection of leukaemia-specific fusion products was shown to be more sensitive and accurate, especially using the newest quantitative PCR technologies. However, chimerism testing is a most valuable tool for detecting relapse when no such specific methods are available and/or when the malignant clone is present at higher cell numbers.
